Trial · NCT03439254
Participant flow36
How many started, completed or left each group, period by period.
1 to 20 of 36
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-blind Phase (18 Months) | STARTED | DB: Placebo | 313 | |
| Double-blind Phase (18 Months) | STARTED | DB: OCA 10 Milligrams (mg) | 296 | |
| Double-blind Phase (18 Months) | STARTED | DB: OCA 10 mg Titrated to OCA 25 mg | 310 | |
| Double-blind Phase (18 Months) | STARTED | OLE: OCA 10 mg (DB Placebo) | 0 | |
| Double-blind Phase (18 Months) | STARTED | OLE: OCA 10 mg (DB OCA 10 mg) | 0 | |
| Double-blind Phase (18 Months) | STARTED | OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) | 0 | |
| Double-blind Phase (18 Months) | COMPLETED | DB: Placebo | 284 | |
| Double-blind Phase (18 Months) | COMPLETED | DB: OCA 10 Milligrams (mg) | 274 | |
| Double-blind Phase (18 Months) | COMPLETED | DB: OCA 10 mg Titrated to OCA 25 mg | 275 | |
| Double-blind Phase (18 Months) | COMPLETED | OLE: OCA 10 mg (DB Placebo) | 0 | |
| Double-blind Phase (18 Months) | COMPLETED | OLE: OCA 10 mg (DB OCA 10 mg) | 0 | |
| Double-blind Phase (18 Months) | COMPLETED | OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) | 0 | |
| Double-blind Phase (18 Months) | NOT COMPLETED | DB: Placebo | 29 | |
| Double-blind Phase (18 Months) | NOT COMPLETED | DB: OCA 10 Milligrams (mg) | 22 | |
| Double-blind Phase (18 Months) | NOT COMPLETED | DB: OCA 10 mg Titrated to OCA 25 mg | 35 | |
| Double-blind Phase (18 Months) | NOT COMPLETED | OLE: OCA 10 mg (DB Placebo) | 0 | |
| Double-blind Phase (18 Months) | NOT COMPLETED | OLE: OCA 10 mg (DB OCA 10 mg) | 0 | |
| Double-blind Phase (18 Months) | NOT COMPLETED | OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) | 0 | |
| Open Label Extension Phase (12 Months) | STARTED | DB: Placebo | 0 | |
| Open Label Extension Phase (12 Months) | STARTED | DB: OCA 10 Milligrams (mg) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03439254/flow